Douglas Pharma aims to double revenue by 2025
The family-owned pharma has a pipeline of new drug products undergoing clinical trials.
Scroll down for video
Douglas Pharmaceuticals is celebrating its 50th birthday in business by setting an ambitious target to boost its annual revenue to $500 million by 2025 from an expected $240 million this financial year.
The west Auckland company was started in 1967 by the late Sir Graeme
Want to read more? It's easy.
Choose your best value subscription option
Individual
Group membership
NBR Marketplace
Yearly Premium Online Subscription
NZ$499.00 / yearly
Monthly Premium Online Subscription
NZ$44.95 / monthly
Smartphone Only Subscription
NZ$24.95 / monthly
Premium Group Membership 10 Users
NZ$350+GST / monthly
$35 per user - Pay by monthly credit card debitPremium Group Membership 20 Users
NZ$600+GST / monthly
$30 per user - Pay by monthly credit card debitPremium Group Membership 50 Users
NZ$1250+GST / monthly
$25 per user - Pay by monthly credit card debitPremium Group Membership 100 Users
NZ$1875+GST / monthly
$18.75 per user - Pay by monthly credit card debitYearly Premium Online Subscription + NBR Marketplace
NZ$499.00 / yearly
Already have an account? Login
Fiona Rotherham & Susan Wood
Thu, 16 Nov 2017
Thu, 16 Nov 2017
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Related News
Related News
Douglas Pharma aims to double revenue by 2025
71650